Hansa Biopharma to Attend Truist Securities BioPharma Symposium
Hansa Biopharma (Nasdaq Stockholm: HNSA) announced its participation in the Truist Securities BioPharma Symposium on November 7 in New York. Chief R&D Officer Hitto Kaufmann will join a panel discussion on 'Inflammatory Insights: Advancing Novel Therapeutics Across Autoimmune and Inflammatory Indications' from 10:30 to 11:20 AM EST.
The company recently completed a 12-month follow-up analysis of the NICE-01 trial for HNSA-5487, their next-generation molecule. Results show the drug effectively reduces IgG levels rapidly, offers redosing potential, and maintains a favorable safety profile. Hansa, a pioneer in immunological treatments, has developed a first-in-class IgG antibody-cleaving enzyme therapy for kidney transplantation in highly sensitized patients.
Hansa Biopharma (Nasdaq Stockholm: HNSA) ha annunciato la sua partecipazione al Truist Securities BioPharma Symposium che si terrà il 7 novembre a New York. Il Chief R&D Officer Hitto Kaufmann parteciperà a un panel di discussione su 'Approfondimenti Infiammatori: Avanzare Nuove Terapie in Indirizzi Autoimmuni e Infiammatori' dalle 10:30 alle 11:20 EST.
L'azienda ha recentemente completato un'analisi di follow-up di 12 mesi dello studio NICE-01 per HNSA-5487, la loro molecola di nuova generazione. I risultati mostrano che il farmaco riduce efficacemente i livelli di IgG rapidamente, offre un potenziale di rivalutazione e mantiene un profilo di sicurezza favorevole. Hansa, pioniera nei trattamenti immunologici, ha sviluppato una terapia con enzima cleaved IgG di prima classe per il trapianto di rene in pazienti altamente sensibilizzati.
Hansa Biopharma (Nasdaq Estocolmo: HNSA) anunció su participación en el Simposio BioPharma de Truist Securities el 7 de noviembre en Nueva York. El Director de I+D Hitto Kaufmann participará en una mesa redonda sobre 'Perspectivas Inflamatorias: Avanzando Nuevas Terapias en Indicaciones Autoinmunes e Inflamatorias' de 10:30 a 11:20 AM EST.
La compañía completó recientemente un análisis de seguimiento de 12 meses del ensayo NICE-01 para HNSA-5487, su molécula de nueva generación. Los resultados muestran que el fármaco reduce eficazmente los niveles de IgG de manera rápida, ofrece potencial de re-dosificación y mantiene un perfil de seguridad favorable. Hansa, pionera en tratamientos inmunológicos, ha desarrollado una terapia con enzima cortadora de IgG de primera clase para el trasplante de riñón en pacientes altamente sensibilizados.
한사 바이오파마 (나스닥 스톡홀름: HNSA)는 11월 7일 뉴욕에서 개최되는 트루이스트 증권 바이오파마 심포지엄에 참여한다고 발표했습니다. 최고 연구개발 책임자인 히토 카우프만이 '염증 통찰력: 자가면역 및 염증 적응증에 대한 새로운 치료제의 발전'에 대한 패널 토론에 10:30부터 11:20 AM EST까지 참여할 예정입니다.
회사는 최근 HNSA-5487, 차세대 분자에 대한 NICE-01 시험의 12개월 후속 분석을 완료했습니다. 결과는 이 약물이 IgG 수치를 신속하게 효과적으로 감소시키고 재투여 가능성을 제공하며 안전성 프로필을 우수하게 유지함을 보여줍니다. 면역학적 치료의 선구자인 한사는 고도로 감작된 환자의 신장 이식을 위한 최초의 IgG 항체 절단 효소 치료제를 개발했습니다.
Hansa Biopharma (Nasdaq Stockholm: HNSA) a annoncé sa participation au Symposium BioPharma de Truist Securities qui se tiendra le 7 novembre à New York. Le directeur de la R&D, Hitto Kaufmann, participera à une discussion de panel sur 'Perspectives Inflammatoires : Avancer des Nouvelles Thérapeutiques à Travers des Indications Auto-immunes et Inflammatoires' de 10h30 à 11h20 EST.
La société a récemment achevé une analyse de suivi de 12 mois de l'essai NICE-01 pour HNSA-5487, sa molécule de nouvelle génération. Les résultats montrent que le médicament réduit efficacement les niveaux d'IgG rapidement, offre un potentiel de redosage et maintient un profil de sécurité favorable. Hansa, pionnière dans les traitements immunologiques, a développé une thérapie à base d'enzyme clivant d'IgG de première classe pour la transplantation rénale chez des patients hautement sensibilisés.
Hansa Biopharma (Nasdaq Stockholm: HNSA) gab seine Teilnahme am Truist Securities BioPharma Symposium bekannt, das am 7. November in New York stattfindet. Chief R&D Officer Hitto Kaufmann wird an einer Podiumsdiskussion mit dem Titel 'Entzündliche Einblicke: Fortschritte bei neuartigen Therapeutika in autoimmunen und entzündlichen Indikationen' von 10:30 bis 11:20 Uhr EST teilnehmen.
Das Unternehmen hat kürzlich eine 12-monatige Follow-up-Analyse der NICE-01-Studie für HNSA-5487, ihr nächsgeneration Molekül, abgeschlossen. Die Ergebnisse zeigen, dass das Medikament effektiv die IgG-Spiegel schnell reduziert, ein Nachdosierungspotenzial bietet und ein günstiges Sicherheitsprofil aufweist. Hansa, ein Pionier in der immunologischen Behandlung, hat eine erstklassige IgG-Antikörper-spaltende Enzymtherapie für Nierentransplantationen bei hochsensibilisierten Patienten entwickelt.
- None.
- None.
Recently Hansa conducted a 12-month follow up analysis of data from the NICE-01 trial of HNSA-5487, the company's next generation molecule. The analysis demonstrates that HNSA-5487 can robustly and very rapidly reduce IgG levels, has redosing potential, and a favorable safety and tolerability profile.
Hansa management will be available for meetings at the conference. If you are interested in meeting with the management team, please contact Hansa Biopharma at ir@hansabiopharma.com.
To learn more about Hansa Biopharma see the latest Corporate Presentation here. The latest investor presentation can be viewed here.
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com
Stephanie Kenney, VP Global Corporate Affairs
media@hansabiopharma.com
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa Biopharma has a rich and expanding research and development program based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in
©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB,
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
20241017_Truist HC Conf_press release_FINAL |
View original content:https://www.prnewswire.com/news-releases/hansa-biopharma-to-attend-truist-securities-biopharma-symposium-302291270.html
SOURCE Hansa Biopharma AB
FAQ
What are the key findings from Hansa Biopharma's NICE-01 trial for HNSA-5487?
When and where is Hansa Biopharma presenting at the Truist Securities BioPharma Symposium?
What is Hansa Biopharma's (HNSA) main therapeutic breakthrough?
